WO2006038647A1 - 補酵素の安定化方法およびその組成物 - Google Patents
補酵素の安定化方法およびその組成物 Download PDFInfo
- Publication number
- WO2006038647A1 WO2006038647A1 PCT/JP2005/018424 JP2005018424W WO2006038647A1 WO 2006038647 A1 WO2006038647 A1 WO 2006038647A1 JP 2005018424 W JP2005018424 W JP 2005018424W WO 2006038647 A1 WO2006038647 A1 WO 2006038647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coenzyme
- substance
- phosphorylated
- suppresses
- buffer
- Prior art date
Links
- 239000005515 coenzyme Substances 0.000 title claims abstract description 146
- 238000000034 method Methods 0.000 title claims abstract description 98
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims description 47
- 239000000126 substance Substances 0.000 claims abstract description 71
- 238000006209 dephosphorylation reaction Methods 0.000 claims abstract description 65
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims description 90
- 108090000790 Enzymes Proteins 0.000 claims description 90
- 230000006641 stabilisation Effects 0.000 claims description 45
- 238000011105 stabilization Methods 0.000 claims description 45
- 238000003018 immunoassay Methods 0.000 claims description 42
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 claims description 41
- 239000000758 substrate Substances 0.000 claims description 41
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 32
- 229910019142 PO4 Inorganic materials 0.000 claims description 32
- 239000008103 glucose Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 32
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 31
- 239000010452 phosphate Substances 0.000 claims description 31
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 30
- 239000000470 constituent Substances 0.000 claims description 30
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 28
- 239000012528 membrane Substances 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 24
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 23
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 150000002016 disaccharides Chemical class 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 239000005720 sucrose Substances 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 17
- 150000004676 glycans Chemical class 0.000 claims description 17
- 229920001282 polysaccharide Polymers 0.000 claims description 17
- 239000005017 polysaccharide Substances 0.000 claims description 17
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 13
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 238000007605 air drying Methods 0.000 claims description 6
- 230000030609 dephosphorylation Effects 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 86
- 239000000872 buffer Substances 0.000 description 83
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 39
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 39
- 235000021317 phosphate Nutrition 0.000 description 26
- 239000007853 buffer solution Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 206010022000 influenza Diseases 0.000 description 17
- 230000001351 cycling effect Effects 0.000 description 16
- -1 diphorase Chemical compound 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 239000001509 sodium citrate Substances 0.000 description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 10
- 102000002278 Ribosomal Proteins Human genes 0.000 description 10
- 108010000605 Ribosomal Proteins Proteins 0.000 description 10
- 244000005700 microbiome Species 0.000 description 9
- 229950006238 nadide Drugs 0.000 description 9
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000606161 Chlamydia Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- CXONXVMMINSQBV-NNYOXOHSSA-N (2r,3r,4s,5r)-5-[[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-2-(3-carbamothioylpyridin-1-ium-1-yl)-4-hydroxyoxolan-3-olate Chemical compound NC(=S)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)[O-])=C1 CXONXVMMINSQBV-NNYOXOHSSA-N 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N 2,5-dimethyl-1h-imidazole Chemical compound CC1=CN=C(C)N1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 4
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 4
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- 241001647372 Chlamydia pneumoniae Species 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000589242 Legionella pneumophila Species 0.000 description 4
- 239000007990 PIPES buffer Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 150000001860 citric acid derivatives Chemical class 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229940115932 legionella pneumophila Drugs 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- 108010073927 12-alpha-hydroxysteroid dehydrogenase Proteins 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IOAOAKDONABGPZ-UHFFFAOYSA-N 2-amino-2-ethylpropane-1,3-diol Chemical compound CCC(N)(CO)CO IOAOAKDONABGPZ-UHFFFAOYSA-N 0.000 description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 239000008001 CAPS buffer Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- LUEWUZLMQUOBSB-ZLBHSGTGSA-N alpha-maltotetraose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-ZLBHSGTGSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003641 trioses Chemical class 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- DFKPJBWUFOESDV-UHFFFAOYSA-N (1->6)-alpha-Galactotetraose Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC2C(C(O)C(O)C(OCC3C(C(O)C(O)C(O)O3)O)O2)O)O1 DFKPJBWUFOESDV-UHFFFAOYSA-N 0.000 description 1
- OLBQXBHLZOAVSV-SPIWUIBRSA-N (2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O[C@@H]4[C@@H](O)[C@H](O)O[C@H](CO)[C@H]4O)[C@@H]3O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O OLBQXBHLZOAVSV-SPIWUIBRSA-N 0.000 description 1
- XYSPNTPTSPNTHM-TVKCVLHLSA-N (2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@H]3O[C@H](OC[C@H]4O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O XYSPNTPTSPNTHM-TVKCVLHLSA-N 0.000 description 1
- DPSWBCAAYVEQQC-OQRKSSCTSA-N (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-[(2R,3R,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O[C@@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)O[C@H](CO)[C@@H](O)[C@@H]2O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O DPSWBCAAYVEQQC-OQRKSSCTSA-N 0.000 description 1
- HQFMTRMPFIZQJF-MBBOGVHQSA-N (3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O[C@@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O1 HQFMTRMPFIZQJF-MBBOGVHQSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- QSESWLKFTMBIPZ-UHFFFAOYSA-N 4'-O-glucosyl-beta-gentiobiose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OCC2C(C(O)C(O)C(O)O2)O)C(O)C1O QSESWLKFTMBIPZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 101150003382 57 gene Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- ODEHMIGXGLNAKK-OESPXIITSA-N 6-kestotriose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 ODEHMIGXGLNAKK-OESPXIITSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-TYASJMOZSA-N ADP-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1OC(O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-TYASJMOZSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 201000005019 Chlamydia pneumonia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- YSVQUZOHQULZQP-UHFFFAOYSA-N Mannosylglucosaminide Natural products NC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 YSVQUZOHQULZQP-UHFFFAOYSA-N 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- FSJSODMMIYGSTK-UHFFFAOYSA-N OCC1OC(OCC2OC(OCC3OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C3O)C(O)C(O)C2O)C(O)C(O)C1O Chemical compound OCC1OC(OCC2OC(OCC3OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C3O)C(O)C(O)C2O)C(O)C(O)C1O FSJSODMMIYGSTK-UHFFFAOYSA-N 0.000 description 1
- FSJSODMMIYGSTK-AGJIYOFVSA-N OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](OC[C@H]3O[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O Chemical compound OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](OC[C@H]3O[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O FSJSODMMIYGSTK-AGJIYOFVSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- NIBVDXPSJBYJFT-VBBCUDLLSA-N Planteose Natural products O(C[C@@H]1[C@H](O)[C@@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O1)[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1 NIBVDXPSJBYJFT-VBBCUDLLSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000393528 Reginella Species 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- BUEBVQCTEJTADB-UHFFFAOYSA-N Sambubiose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)CO1 BUEBVQCTEJTADB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- UQBIAGWOJDEOMN-UHFFFAOYSA-N Sophorotriose Chemical compound OC1C(O)C(CO)OC(O)C1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 UQBIAGWOJDEOMN-UHFFFAOYSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
- LNRUEZIDUKQGRH-UHFFFAOYSA-N Umbelliferose Natural products OC1C(O)C(CO)OC1(CO)OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 LNRUEZIDUKQGRH-UHFFFAOYSA-N 0.000 description 1
- UUQINGLDFWYORW-RJVMBZMCSA-N [3)-beta-D-Glcp-(1->]5 Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@H]4[C@@H]([C@@H](CO)O[C@@H](O)[C@@H]4O)O)O[C@H](CO)[C@H]3O)O)O[C@H](CO)[C@H]2O)O)O[C@H](CO)[C@H]1O UUQINGLDFWYORW-RJVMBZMCSA-N 0.000 description 1
- WKSUSMNNBQFESD-UHFFFAOYSA-N [5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy-[[3-hydroxy-5-(6-oxo-3h-purin-9-yl)-4-phosphonooxyoxolan-2-yl]methoxy]phosphoryl] phosphate Chemical compound NC(=O)C1=CC=C[N+](C2C(C(O)C(COP([O-])(=O)OP(O)(=O)OCC3C(C(OP(O)(O)=O)C(O3)N3C4=C(C(N=CN4)=O)N=C3)O)O2)O)=C1 WKSUSMNNBQFESD-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-BTLHAWITSA-N alpha,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-BTLHAWITSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- FBJQEBRMDXPWNX-SMGIPPFUSA-N alpha-D-Galp-(1->6)-alpha-D-Galp-(1->6)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-SMGIPPFUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- OCIBBXPLUVYKCH-QXVNYKTNSA-N alpha-maltohexaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O OCIBBXPLUVYKCH-QXVNYKTNSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- DBTMGCOVALSLOR-AKJQSPAISA-N beta-D-Glcp-(1->3)-beta-D-Glcp-(1->3)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-AKJQSPAISA-N 0.000 description 1
- FBJQEBRMDXPWNX-CFCQXFMMSA-N beta-D-Glcp-(1->6)-beta-D-Glcp-(1->6)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](O)O2)O)O1 FBJQEBRMDXPWNX-CFCQXFMMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- FTNIPWXXIGNQQF-XHCCAYEESA-N cellopentaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FTNIPWXXIGNQQF-XHCCAYEESA-N 0.000 description 1
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000007999 glycylglycine buffer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- PIBXBCFBUUZPRF-UHFFFAOYSA-N isocyclomaltohexaose Natural products OCC1OC2OCC3OC(OC4C(O)C(O)C(OC4CO)OC5C(O)C(O)C(OC5CO)OC6C(O)C(O)C(OC6CO)OC7C(O)C(O)C(OC7CO)OC1C(O)C2O)C(O)C(O)C3O PIBXBCFBUUZPRF-UHFFFAOYSA-N 0.000 description 1
- FOMCONPAMXXLBX-MQHGYYCBSA-N isopanose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H](O)[C@H]([C@H](O)[C@@H](O)C=O)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOMCONPAMXXLBX-MQHGYYCBSA-N 0.000 description 1
- VAWYEUIPHLMNNF-UHFFFAOYSA-N kestotriose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 VAWYEUIPHLMNNF-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- QIGJYVCQYDKYDW-LCOYTZNXSA-N laminarabiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-LCOYTZNXSA-N 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- DJMVHSOAUQHPSN-UHFFFAOYSA-N malto-hexaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(OC4C(C(O)C(O)C(CO)O4)O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 DJMVHSOAUQHPSN-UHFFFAOYSA-N 0.000 description 1
- FJCUPROCOFFUSR-UHFFFAOYSA-N malto-pentaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 FJCUPROCOFFUSR-UHFFFAOYSA-N 0.000 description 1
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- FJCUPROCOFFUSR-GMMZZHHDSA-N maltopentaose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 FJCUPROCOFFUSR-GMMZZHHDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- HQFMTRMPFIZQJF-UAEIHXJMSA-N neokestose Natural products OC[C@H]1O[C@@](CO)(OC[C@H]2O[C@@H](O[C@]3(CO)O[C@H](CO)[C@@H](O)[C@@H]3O)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O HQFMTRMPFIZQJF-UAEIHXJMSA-N 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- IFZDCYWLUQXIAN-UHFFFAOYSA-N phosphoric acid;7h-purin-6-amine;pyridine-3-carboxamide Chemical compound OP(O)(O)=O.NC(=O)C1=CC=CN=C1.NC1=NC=NC2=C1NC=N2 IFZDCYWLUQXIAN-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- NIBVDXPSJBYJFT-ZQSKZDJDSA-N planteose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 NIBVDXPSJBYJFT-ZQSKZDJDSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- BUEBVQCTEJTADB-IGQSMMPPSA-N sambubiose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1 BUEBVQCTEJTADB-IGQSMMPPSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- YSVQUZOHQULZQP-OCEKCAHXSA-N trehalosamine Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YSVQUZOHQULZQP-OCEKCAHXSA-N 0.000 description 1
- LNRUEZIDUKQGRH-YZUCMPLFSA-N umbelliferose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 LNRUEZIDUKQGRH-YZUCMPLFSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/04—Use of additives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/008—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions for determining co-enzymes or co-factors, e.g. NAD, ATP
Definitions
- the present invention relates to a method for stabilizing phosphate-coenzyme, characterized by comprising at least a substance that suppresses the dephosphorylation reaction of phosphate-coenzyme and a phosphorylated coenzyme. And a stabilizing method, a storage method, and a stabilizing composition.
- the present invention is used in fields such as clinical diagnosis, food inspection, and biological component inspection.
- Non-patent Document 1 there is a problem that the sensitivity of the test reagent is lowered due to a decrease in the total amount of coenzyme.
- the coenzyme is stored under extremely low temperature conditions such as freezing or refrigeration, and the reagent containing the coenzyme is freeze-dried, or amine base or as a stabilizer in the solution state.
- Coenzymes are also used as immunological laboratory test reagents.
- a coenzyme cycling method is known as a method for detecting an alkaline phosphatase (ALP) -labeled antibody using NADP or NADPH as a substrate as an enzyme immunoassay (Patent Document 3).
- ALP alkaline phosphatase
- NADPH alkaline phosphatase
- Test with NADP or NADPH, alcohol dehydrogenase, diphorase, alcohol, and tetrazolium salt enzyme cycling reagents For example, when NADP is used as a substrate for ALP, NAD is generated from NA DP by ALP, and the resulting NAD is converted to NA DH by alcohol dehydrogenase and alcohol.
- the tetrazolium salt returns to NAD again, and the reaction proceeds again from NAD to NADH.
- the formazan dye generated from the tetrazolium salt accumulates in the reaction solution, and the ALP activity can be measured by measuring the amount of this dye.
- reagents also have problems with the stability of the coenzyme, and like biochemical test agents, in order to store the reagent for a long time, the coenzyme is stored under extremely low temperature conditions such as freezing or refrigeration, Coenzymes have been stored in a lyophilized state. Attempts have also been made to stabilize by selecting the type of buffer.
- ALP is well known as a labeling enzyme widely used in enzyme immunoassay
- a method for detecting ALP with high sensitivity is desired.
- the technology for increasing the sensitivity is effective not only for the purpose of measuring a minute amount but also for reducing the amount of sample or shortening the measurement time, and is the most desired technology in this field. .
- Patent Document 1 Japanese Patent No. 3470099
- Patent Document 2 Japanese Patent Laid-Open No. 2001-61498
- Patent Document 3 JP-A-6-303996
- Non-Patent Document 1 Protein / Enzyme Basic Experiment, Nanedo, p. 426
- An object of the present invention is to provide a method for stabilizing a phosphorylated coenzyme for a long period of time, particularly near room temperature.
- the present invention is a method for stabilizing phosphate coenzyme, comprising at least coexisting a substance that inhibits the dephosphorylation reaction of phosphate coenzyme and a phosphorylated coenzyme. It is related to the stability method,
- a method for stabilizing phosphate coenzyme comprising at least a substance that inhibits the dephosphorylation reaction of phosphate coenzyme and a phosphorylated coenzyme.
- Substance power to suppress dephosphorylation reaction Lattose, trehalose, maltose, sucrose force It is one or a combination of two or more selected from the group consisting of the above (5) Stabilization method,
- a stable composition of phosphate coenzyme comprising at least a substance that inhibits the dephosphorylation reaction of phosphate coenzyme, and a phosphorylated coenzyme ⁇ composition
- a stable composition of dried phosphate coenzyme comprising at least a substance that inhibits the dephosphorylation reaction of phosphate coenzyme, and a phosphorylated coenzyme Dried and stable composition
- the substance power for suppressing the dephosphorylation reaction is one or a combination of two or more selected from the group consisting of ratatoses, trehalose, maltose, and sucrose power.
- a method for stabilizing a phosphorylated coenzyme for enzyme cycling characterized by coexisting a phosphorylated coenzyme, at least a substance that suppresses the dephosphorylation reaction of phosphorylated coenzyme
- a method for stabilizing a phosphorylated coenzyme for enzyme cycling characterized by coexisting only a phosphorylated coenzyme, at least a substance that suppresses the dephosphorylation reaction of the phosphorylated coenzyme,
- Phosphoric acid coenzyme stability for enzyme cycling is determined to be more than 70% phosphorylated coenzyme after 3 months at 32 ° C and dephosphorylation in the remaining phosphorylated coenzyme.
- the stability of phosphoric acid coenzyme for enzyme cycling is determined to be at least 70% phosphorylated coenzyme after 6 months at 32 ° C and dephosphorylation in the remaining phosphorylated coenzyme.
- Phosphorus coenzyme stability for enzyme cycling is determined to be at least 70% phosphorylated coenzyme after 1 year at 32 ° C and dephosphorylation in the remaining phosphorylated coenzyme.
- Nicotinamide adenine dinucleotide phosphate power Nicotine amide adenine dinucleotide phosphate and Z or thionicotinamide adenine dinucleotide phosphate
- Nicotinamide adenine dinucleotide phosphate power Nicotine amide adenine dinucleotide phosphate and Z or thionicotinamide adenine dinucleotide phosphate
- a flow-through type simple immunoassay device provided with a liquid feeding device so that an enzyme substrate is automatically added after the enzyme labeling reagent has permeated through the membrane on which the antibody or antigen is immobilized.
- microorganism is one or more selected from Mycoplasma-humor, Hemophilus influenza, Streptococcus pneumoniae, Chlamydia pneumoniae, and Chlamydia tracomatus Legionella pneumophila.
- the enzyme-labeling reagent is characterized in that no washing solution is added after permeating the membrane on which the antibody or antigen is immobilized and before the enzyme substrate is automatically added.
- the substance power for suppressing the dephosphorylation reaction is one or a combination of two or more selected from the group consisting of ratatoses, trehalose, maltose, and sucrose power. Stabilization method,
- the substance power for suppressing the dephosphorylation reaction is one or a combination of two or more selected from the group consisting of ratatoses, trehalose, maltose, and sucrose power.
- NADP Phosphorylated coenzyme power nicotinamide adenine dinucleotide phosphate
- the stabilization method of the present invention exhibits an effect of stabilizing a coenzyme for a long period of time at room temperature, for example, when used for measuring ALP activity. Therefore, it is very effective for putting a test drug using a coenzyme into a POC test drug.
- FIG. 2 is a diagram of a flow-through type simple immunoassay device provided with a liquid feeding device so that an enzyme substrate is automatically added.
- FIG. 2 A flow-through type device provided with a siphon-type liquid delivery device so that the enzyme substrate is automatically added after the enzyme labeling reagent of the present invention has permeated through the membrane on which the antibody or antigen is immobilized. It is a figure of a simple immunity measuring device.
- NADP for example, NADP, thioNADP, acetylyl NADP, deamino NADP, deamide NADP, or a combination of one or two or more coenzymes selected from the group of force is preferable.
- NADP or NADP H is more preferable, and NADP is particularly preferable.
- a commercially available product may be used as it is as long as it is highly pure, but if necessary, a commercially available powder of fermenting enzyme dissolved in an appropriate solvent and purified by column purification or the like may be used. Examples of impurities to be noted are phosphorylated and coenzymes.
- the amount of the non-phosphorylated coenzyme, which is an impurity is preferably 1% or less, and more preferably 0.5% or less, relative to the amount of phosphate coenzyme that is the target of stability in % Or less is particularly preferable.
- the substance that suppresses the dephosphorylation reaction in the present invention is a substance that has an action of suppressing the dissociation of at least the phosphate group bonded to the 2-position of ribose present in the structure of the phosphorylated coenzyme. If it is not limited at all, ⁇ may have other actions as well. Examples of the other action include an action of suppressing the decomposition of the bond between the ribose moiety and the base moiety. Specific examples of the substance include saccharide and Z or sugar alcohol, and saccharide is particularly preferable.
- a polysaccharide is preferable.
- a polysaccharide containing glucose in its structure is particularly preferable.
- Specific examples include sucrose, trehalose, ratatoses, maltose, a-cyclodextrin, j8-cyclodextrin, ⁇ -cyclodextrin, methyl-1-cyclodextrin, hydroxypropyl cyclodextrin, maltodextrin, manoletotriose, Maltotetraose, maltopentaose, maltohexaose, manoletoheptaose, isomaretose, isomaretotriose isomanoretetraose, isomaltopentose, isomaltohexaose, nonose, isopanose, sophorose, sophorotriose, Sophorotetraose, Sophoropentaose, Sophoro
- disaccharides containing glucose in the structure More preferred are disaccharides containing glucose in the structure, and most preferably one or a combination of two or more selected from the group consisting of lactose, trehalose, maltose and sucrose. Ratatoose is particularly preferable. Further, as another embodiment, there are cases where it is preferable to use treno and loin. In another embodiment, maltose is preferred, and sucrose is preferred.
- a combination of latatoose or trehalose and a disaccharide containing glucose in the other structure is good.
- latatose is one or more selected from trehalose, maltose, and sucrose
- the concentration range of the substance that suppresses the dephosphorylation reaction during storage is not particularly defined, and the upper limit value may be anything as long as it is not higher than the saturated dissolution concentration.
- the lower limit is preferably 0.1% or more, more preferably 0.5% or more, and particularly preferably 1% or more.
- Stabilization of phosphate coenzyme in the present invention means a state in which phosphate coenzyme maintains high purity during the storage period. Specifically, it means a state in which the phosphorylated coenzyme is maintained at a high purity so that a necessary and sufficient amount as an alkaline phosphatase substrate is contained during the storage period and the increase in knock ground is suppressed to a low level.
- the amount of phosphorylated coenzyme is 70% or more, and the increase rate of non-phosphorylated coenzyme relative to the amount of phosphorylated coenzyme at the start of storage is 1% or less.
- the amount of phosphorylated coenzyme is 80% or more, and the amount of coenzyme that is not phosphorylated with respect to the amount of phosphate coenzyme at the start of storage.
- a more preferable embodiment is that the state where the increase rate is 1% or less is maintained for a long time. As such a long period, 3 months or more, 6 months or more, or 12 months or more is mentioned as a preferred period, and among them, 6 months or more is mentioned as a particularly preferred period.
- the method for stabilizing a phosphorylated coenzyme according to the present invention is characterized in that at least a phosphorylated coenzyme and a substance that suppresses the dephosphorylation reaction coexist.
- the ratio of the coexistence of the phosphorylated coenzyme and the substance that suppresses the dephosphorylation reaction is as follows. Phosphorylated coenzyme is sufficiently stabilized under the desired storage conditions and phosphorylated coenzyme under the desired sample measurement conditions.
- the ratio is not particularly limited as long as it does not inhibit the action of the enzyme, but for example, the ratio of the substance power that suppresses dephosphorylation reaction to one molecule of phosphorylated coenzyme is 0.001 molecule. More preferably, the ratio of 10 6 molecules to 0.001 molecules is optimal, and the ratio of 10 6 molecules force is also 0.002 molecules.
- the concentration range of phosphoric acid coenzyme added to the buffer solution is not particularly limited, but the lower limit is preferably O.lmM or more, more preferably 0.5 mM or more. Particularly preferred is ImM or higher. Further, the upper limit is preferably 1 mM or less, more preferably 500 mM or less, and even more preferably 200 mM or less.
- the buffer is not particularly defined and any buffer can be used.
- oxalate buffer ethylenediamine tetraacetate buffer, maleate buffer, aspartate buffer, phosphate buffer, asparagine buffer, Glycine buffer, pinolevic acid buffer, pyrophosphate buffer, malonate buffer, phthalate buffer, fumarate buffer, tartrate buffer, citrate buffer, furan carboxylate buffer, ⁇ -alanine buffer , ⁇ : ⁇ 8'-dimethyl daltaric acid buffer, formic acid buffer, lactic acid buffer, ⁇ -aminobutyric acid buffer, norebituric acid buffer, benzoic acid buffer, succinic acid buffer, ⁇ -aminocaproic acid buffer, acetic acid buffer Solution, propionate buffer solution, malate buffer solution, pyridine buffer solution, histidine buffer solution, force codylate buffer solution, carbonate buffer solution, hydroxyimidazole buffer solution, glycerol phosphate buffer solution, ethylenediamine buffer solution, imidazole buffer solution, Arsenate buffer
- the pH of the buffer solution should be neutral in the case of a reduced phosphorylated coenzyme.
- a pH of 7.5 to 11 is appropriate.
- neutral to acidic is preferable, preferably pH 2 to pH 7.5 is optimal, and pH 3 to 7 is optimal.
- a method of adding a preservative such as azinatrium procrine to the stabilization method of the present invention for the purpose of further improving general storability can also be mentioned as a suitable method.
- a method of obtaining a dried composition for storage by drying these solutions can be mentioned.
- the phosphorylated coenzyme stabilization composition of the present invention is prepared as a composition containing at least a substance that suppresses the dephosphorylation reaction of phosphorylated coenzyme and a phosphorylated coenzyme according to the stabilization method described above. Anything that has been done.
- a composition in which the buffer, the preservative and the like are further added to the composition is also preferable.
- the composition may be liquid or dry, but is preferably dry.
- the dry composition may be obtained by mixing dried products. A force obtained by preparing the solution once and then drying it is preferable.
- the drying method is not particularly specified, and examples thereof include freeze drying, air drying, heat drying, reduced pressure drying and the like, preferably freeze drying and air drying, and particularly preferably air drying.
- the drying temperature is not particularly specified as long as the phosphorylated coenzyme is not degraded, and it is preferable if it is -80 ° C to 100 ° C. 50 ° C to 70 ° C is good. Further, the drying time may be set as appropriate using the moisture drying degree as an index according to the drying conditions. The lower the moisture content, the better the moisture dryness index, but it is preferably 10% or less, more preferably 5% or less. Optimally 3% or less 1 % Or less is very preferable.
- the storage temperature of the stabilizing composition of the present invention is not particularly defined as long as it is set according to the purpose, but the upper limit temperature is preferably 50 ° C or less, more preferably 40 ° C or less. Preferred is 37 ° C or less, more preferred is 32 ° C or less, and particularly preferred is 30 ° C or less. There is no special requirement for the lower limit temperature, but from a practical point of view, 20 ° C or higher is preferable 10 ° C or higher is more preferable 0 ° C or higher is more preferable 4 ° C The above is particularly preferable. 10 ° C or more is most preferable.
- a feature of the stability method of the present invention is that it can be stored stably at room temperature, for example, 20 ° C to 40 ° C, 4 ° C to 37 ° C, 10 ° C to 32 ° C. There is a feature.
- a coenzyme that can be stored at room temperature for a long time, similarly at room temperature It is possible to provide a sensitive ALP activity measurement method that can be stored for a long period of time.
- a method for measuring ALP activity for example, a reaction solution containing 12 ⁇ -hydroxysteroid dehydrogenase, diaphorase, cholic acid, nitroblue tetrazolium dissolved in a buffer solution may be stored in a dry state. Re-dissolve NADP, add ALP to the reaction mixture, and incubate at room temperature or 37 ° C for a certain time.
- the amount of dye that increases in the solution may be determined by measuring the amount of increase per unit time or the accumulated absolute amount with a spectrophotometer or by visual inspection.
- a detection reagent can be used widely in a variety of inspection fields as described above, such as a detection kit containing the detection reagent.
- a detection reagent for Escherichia coli 0157 that can be stored at room temperature is mentioned as an example.
- kits 0157 gene probe-immobilized plate, specimen extract, digoxigenin-labeled nucleic acid, anti-digoxigen ALP-labeled antibody, washing solution, NALP dry product for ALP detection, enzyme dry product for ALP detection
- An ALP detection reagent solution kit is available.
- the probe nucleic acid for detecting the Escherichia coli Ol 57 gene was immobilized on a plastic plate in advance.
- the nucleic acid was extracted from the sample E. coli 0157 on the 0157 gene probe immobilization plate. Incubate at room temperature or 37 ° C for a certain period of time. Wash the plate with washing solution, then add digoxigenin-labeled nucleic acid in a region complementary to the E. coli 0157 gene and in a region different from the probe on the plate solid phase, and incubate at room temperature or 37 ° C for a certain period of time .
- wash the plate add anti-digoxigen ALP-labeled antibody, and incubate at room temperature or 37 ° C for a period of time.
- After washing the plate to detect the anti-digoxigen ALP-labeled antibody-digoxigenin nucleic acid complex formed on the solid phase, detect ALP containing 12 ⁇ -hydroxysteroid dehydrogenase, diaphorase, cholic acid, and nitroblue tetrazolium.
- ALP detection reaction solution prepared by re-dissolving the dried enzyme product and NADP dried product for ALP detection with ALP detection reagent solution, and incubate at room temperature or 37 ° C for a fixed time.
- the amount of formazan dye developed on the plate is read with an optical instrument such as a plate reader or judged visually to confirm the presence of E. coli 0157 in the sample. If present, the color develops strongly due to the ALP activity supported by the 0157 gene. If it does not exist, it will not develop or become very small.
- a substance that suppresses dephosphorylation reaction is used, and at least to suppress dephosphorylation reaction of phosphorylated coenzyme.
- a long-term stable storage method for phosphorylated coenzymes using polysaccharides that contain darcos as a constituent, and at least substances that suppress the dephosphorylation reaction of phosphorylated coenzymes is within the scope of the present invention.
- the stabilized coenzyme of the present invention can be applied to a simple immunoassay apparatus using an enzyme cycling method, and the simple immunoassay apparatus is also within the scope of the present invention.
- the principle of the simplified immunoassay device includes the immunochromatography method and the flow-through method, but the flow-through method is preferred.
- a simple immunoassay device for example, when the flow-through method is taken as an example, an antibody having a binding ability to a substance to be measured is fixed on the membrane in advance, and the membrane is placed on a material capable of absorbing water.
- the membrane In order to capture the substance to be measured on the membrane, for example, another enzyme-labeled antibody capable of binding to the object to be measured and the substance to be measured are reacted in advance on the membrane.
- the solution containing the substance to be measured is dropped, and then the liquid is absorbed and the membrane-like liquid is substantially eliminated. Drip. Next, after the liquid is substantially lost, the cleaning liquid is dropped as a cleaning operation. Similarly, after the cleaning liquid on the film is exhausted, the enzyme substrate solution is added.
- the enzyme contained in the complex formed on the membrane reacts with the enzyme substrate to confirm the formation of the pigment on the membrane.
- a plurality of liquids are added to the simplified immunoassay device at substantially the same time.
- the liquid is sequentially added onto the membrane by the built-in automatic liquid feeder.
- the enzyme-labeled antibody and enzyme substrate solution are mixed on the membrane, the presence or absence of the substance to be measured is determined. Regardless of color development and non-specific background, in order to avoid this, we have invented a simple immunoassay device that incorporates an automatic liquid delivery device that minimizes contact between the two. is there.
- the enzyme-labeled antibody solution When the enzyme-labeled antibody solution and the enzyme substrate solution are simultaneously added to the apparatus, the enzyme-labeled antibody solution first permeates the membrane over a certain period of time, and after the permeation has substantially finished, the enzyme substrate solution is added. Any device can be used as long as it can provide a time difference.For example, when an enzyme substrate solution is added, the solution is shielded with a water-soluble filter before the solution reaches the membrane. In addition, there is a method in which the enzyme substrate solution is added to the membrane after a certain time when the water-soluble filter is dissolved.
- a water-soluble filter is one in which an enzyme substrate solution dissolves the water-soluble filter and does not flow for a certain period of time, but flows out at a certain point in time, and can be used as long as it does not substantially affect the enzyme reaction.
- a film filter having a water-soluble property is preferable.
- the film-like material having water-soluble properties examples include a polybulualcohol film, a pullulan film, a hydroxypropylcellulose film and the like, and a polybulualcohol film is preferable.
- these water-soluble filters are provided in the lower part of the cylindrical enzyme substrate solution addition tank and the enzyme base solution is added, the liquid does not flow for a certain period of time while dissolving the water-soluble filter, and then the liquid flows out.
- the time during which the liquid does not flow is preferably between 10 seconds and 10 minutes, preferably between 30 seconds and 5 minutes.
- the siphon in the present invention is a tube having an opening at the lower part of the enzyme substrate solution addition tank.
- the tube extends upward from the opening and then descends again, and the other opening of the tube leads to the confirmation window. It is acceptable if it has a structure at the site and a filter for adjusting the flow rate of the enzyme substrate solution is provided between the lower part and the upper end of the enzyme substrate solution addition tank.
- a filter for adjusting the flow rate of the enzyme substrate solution is provided between the lower part and the upper end of the enzyme substrate solution addition tank.
- any flow rate adjusting filter can be used as long as it slowly flows to the bottom of the addition tank after the enzyme substrate is added to the enzyme substrate solution addition tank, and water-soluble substances are dried on the filter paper.
- Any material can be used for the filter paper as long as it has the ability to allow the liquid to permeate after the water-soluble substance is re-dissolved.
- paper, glass, polyester, polystyrene, and nylon are preferable. Paper or glass is preferable.
- water-soluble substances include sugars, proteins, and synthetic polymers.
- sugars include high-molecular polysaccharides such as dextran, pullulan, and agar, disaccharides such as sucrose, ratatose, and maltose, and glucose and galactose. Monosaccharides, and high molecular weight polysaccharides are preferred, and dextran is more preferred.
- the protein include albumin and globulin
- examples of the synthetic polymer include polyethylene glycol, polybutylpyrrolidone, polybulal alcohol, and hydroxypropylcellulose.
- the liquid flow rate should be adjusted appropriately according to the concentration of the water-soluble substance at the time of drying. Good liquid flow time should be between 10 seconds and 10 minutes, preferably between 30 seconds and 5 minutes U.
- a swab is collected from a nasal cavity with a cotton swab, and the influenza antigen adhering to the swab is used as an interface with an influenza antigen extract. Suspend in an alkaline phosphatase-labeled anti-influenza antibody solution containing activator, appropriate buffer and salts to obtain an influenza antigen suspension.
- L7ZL12 should be used as the ribosomal protein. It is particularly effective in Mycoplasma-humor, Hemophilus influenza, Streptococcus pneumonia, Chlamydia pneumonia, Chlamydia tracomatus, and Reginella pneumophila, which require high specificity and high binding power. Mycoplasma-humor or Regionella pneumophila are preferred, more preferably antibodies against Mycoplasma pneumonia are used.
- a solution prepared by dissolving NADP (manufactured by Oriental Yeast Co., Ltd.) as a coenzyme to 1.25 mM in a 20 mM sodium citrate buffer (pH 6.5) containing 5% ratatoose was prepared.
- solutions prepared by dissolving NA DP in 1.25 mM in 20 mM sodium citrate buffer (pH 6.5) were prepared, and a total of five types of solutions were prepared.
- This solution was dispensed 201 by 1 in a microtube and dried under conditions of 30 ° C and 15% humidity for 5 hours. After drying, in an aluminum bag containing the desiccant together with the microtube, 4. Stored at C, 25 ° C, 32 ° C, 37 ° C, 42 ° C.
- Cyclic reaction solution 500 1 containing NADP re-dissolved was heated in a test tube at 37 ° C for 3 min, and dissolved in 10 mM PIPES (pH 8.5) 1777.6 U / ml Bacillus sphaericus-derived 12 ⁇ -hydroxysteroid dehydrogenase 5 ⁇ l of Asahi Kasei Pharma Co., Ltd. was added and reacted at 37 ° C. for 5 minutes. 0.5% dodecyl Stop the reaction by adding 250 1 of sodium sulfate solution, and measure the absorbance of the reaction solution at 550 nm.
- Enzyme cycling reaction prepared in (2) Add the previously prepared diluted NADP redissolved solution 20 1 to lml of the alkaline phosphatase derived from small intestine of the bovine small intestine. The reaction was allowed to proceed at 37 ° C for 5 minutes. The reaction was stopped by adding 2501 of a 0.5% sodium dodecyl sulfate solution, the absorbance of the reaction solution was measured at 550 nm, and the measured value at the start of storage of NADP was taken as 100%, and the remaining% was increased.
- NADP Oriental as a coenzyme in 20 mM sodium citrate buffer (pH 6.5) containing 10% trehalose, 10% maltose and 10% sucrose instead of 5% latato as described in Example 1
- Three types of solutions prepared by dissolving Yeast Co., Ltd.) to 1.25 mM were prepared and tested in the same manner.
- condition 1 10% ratatoose and 20% trehalose
- condition 2 10% ratatoose and 20% maltose
- condition 3 20% trehalose and 20% maltose
- condition 4 10 Dissolve NADP (Oriental Yeast Co., Ltd.) as a coenzyme to 1.25 mM in 20 mM sodium citrate buffer (PH 6.5) containing 20% ratatoose, 20% trehalose and 20% maltose, respectively.
- PH 6.5 sodium citrate buffer
- condition 1 100 99 101 92 84 45 condition ⁇ ⁇ ⁇ 2 100 98 98 95 86 50 condition 3 100 99 100 97 88 45 condition 4 100 100 101 101 90 59 experimental control 100 91 88 76 43 31
- NADP manufactured by Oriental Yeast Co., Ltd.
- NADP manufactured by Oriental Yeast Co., Ltd.
- Two types of solutions prepared by dissolving in the manner described above were prepared, and the solutions were dispensed 201 by 1 in a tube and dried for 5 hours at 30 ° C and 15% humidity. After drying, measure the background, ALP activity, and remaining NADP after storage for 6 months at 4 ° C, 25 ° C, and 35 ° C in an aluminum bag containing the desiccant together with the microtube. did.
- Anti-influenza A virus monoclonal antibody (Fitzgerald) One of the two was spotted on a 25 mm x 30 mm-trocellulose membrane (Whatman) with 1 ⁇ l of a 2 mg / ml antibody solution. It was dried at ° C for 30 minutes. The dried nitrocellulose membrane was placed on a water absorbing pad, and the upper lid was placed so that the spot portion coincided with the confirmation window previously opened in the lid.
- a water-soluble filter KC40 manufactured by Aicello Chemical Co., Ltd. made of polybulal alcohol as shown in Fig. 1 is attached to the lower part of the enzyme substrate solution addition tank, and the enzyme substrate inlet is attached to the upper lid opening of the simple immunoassay device. A measuring device was created.
- Another 0.15 mg of anti-influenza A virus monoclonal antibody was labeled with a commercially available alkaline phosphatase labeling kit to obtain an anti-influenza A virus enzyme-labeled antibody.
- This labeled antibody was diluted 4000 times with Tris-HC1 buffer (pH 7.5) containing 2% BSA to prepare an enzyme-labeled antibody diluted solution.
- Influenza A virus antigen H3N2 0.75mg / ml (HyTest) is diluted to 0.1 ⁇ g / ml in PBS containing 0.2% BSA and 0.1% TritonX-100, and 50L of this is applied to a cotton swab. A simulated specimen was soaked. As an experimental control, a cotton swab soaked with 50 L of diluent was used.
- a swab soaked with influenza antigen was placed in 0.2 mL of enzyme-labeled antibody diluent, stirred well, and then added to the confirmation window of the previously prepared simple immunoassay device. Without stopping, 500 L of the enzyme cycling reaction solution of Example 1 was added to the enzyme substrate solution addition tank. Ten minutes after the addition, the presence or absence of a blue pigment was visually confirmed on the nitrocellulose membrane. Result
- Example 6 an anti-influenza A virus monoclonal antibody was immobilized on a -trocellulose membrane and covered.
- As an enzyme substrate solution addition tank a filter paper soaked with 40% sucrose solution and dried is attached to the upstream part of the siphon structure shown in Fig. 2, and the enzyme substrate inlet is attached to the upper lid opening of the simple immunoassay device.
- An immunoassay device was created. The subsequent operation was carried out in the same manner as in Example 6, and the presence or absence of blue V and pigment was visually confirmed on the nitrocellulose membrane.
- the present invention provides a method for stabilizing a phosphorylated coenzyme, particularly near room temperature, and can be suitably used in fields such as clinical diagnosis, food inspection, and biological component inspection.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006539313A JP4986281B2 (ja) | 2004-10-05 | 2005-10-05 | 補酵素の安定化方法およびその組成物 |
US11/576,048 US7879567B2 (en) | 2004-10-05 | 2005-10-05 | Method for stabilizing coenzyme and composition therefor |
US12/977,874 US8026075B2 (en) | 2004-10-05 | 2010-12-23 | Method for stabilizing coenzyme and composition thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-292710 | 2004-10-05 | ||
JP2004292710 | 2004-10-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/576,048 A-371-Of-International US7879567B2 (en) | 2004-10-05 | 2005-10-05 | Method for stabilizing coenzyme and composition therefor |
US12/977,874 Division US8026075B2 (en) | 2004-10-05 | 2010-12-23 | Method for stabilizing coenzyme and composition thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038647A1 true WO2006038647A1 (ja) | 2006-04-13 |
Family
ID=36142719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/018424 WO2006038647A1 (ja) | 2004-10-05 | 2005-10-05 | 補酵素の安定化方法およびその組成物 |
Country Status (3)
Country | Link |
---|---|
US (2) | US7879567B2 (ja) |
JP (1) | JP4986281B2 (ja) |
WO (1) | WO2006038647A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010000027A (ja) * | 2008-06-19 | 2010-01-07 | Denka Seiken Co Ltd | 新規検査方法及びそれに用いる検査キット |
JP2021001890A (ja) * | 2015-10-07 | 2021-01-07 | セルマ・ダイアグノスティクス・アンパルトセルスカブSelma Diagnostics Aps | デジタル計数のためのフローシステムおよび方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879567B2 (en) * | 2004-10-05 | 2011-02-01 | Asahi Kasei Pharma Corporation | Method for stabilizing coenzyme and composition therefor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5743684A (en) * | 1980-08-29 | 1982-03-11 | Toyo Jozo Co Ltd | Preparation of maltose dehydrogenase |
JPH03505261A (ja) * | 1989-03-23 | 1991-11-14 | バンス,ロジャー・アブラハム | 液体移送装置 |
JPH10276785A (ja) * | 1997-03-31 | 1998-10-20 | Kureha Chem Ind Co Ltd | 組換え型トレハロースホスホリラーゼをコードする遺伝子、その遺伝子を含むベクター、その遺伝子で形質転換された形質転換体及びこの形質転換体を用いて組換え型トレハロースホスホリラーゼを製造する方法 |
WO2001094370A1 (fr) * | 2000-06-07 | 2001-12-13 | Wako Pure Chemical Industries, Ltd. | Derives de coenzymes et enzymes appropries |
JP2005304483A (ja) * | 2004-03-24 | 2005-11-04 | Asahi Kasei Pharma Kk | アルカリフォスファターゼ測定法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4927717A (ja) * | 1972-06-26 | 1974-03-12 | ||
CA1102225A (en) * | 1976-09-13 | 1981-06-02 | Ivan E. Modrovich | Stabilized liquid enzyme and coenzyme compositions and method of preparing same |
DE2814154A1 (de) * | 1978-04-01 | 1979-10-11 | Behringwerke Ag | Stabilisierte nicotinamid-nucleotide und verfahren zu ihrer herstellung |
CA1187388A (en) * | 1978-09-20 | 1985-05-21 | American Monitor Corporation | Stabilization of working reagent solutions containing nadh, nadph, and/or enzymes, and the use of such stabilized reagents in enzymes or substrate assays |
JPS5874696A (ja) * | 1981-10-30 | 1983-05-06 | 株式会社 ヤトロン | アデノシン三リン酸の安定化方法 |
JPS5982398A (ja) * | 1982-11-01 | 1984-05-12 | Toyobo Co Ltd | 補酵素の安定化法 |
JPS61212300A (ja) * | 1985-03-15 | 1986-09-20 | Unitika Ltd | 保存安定性に優れたアルコ−ル検出用試験片 |
JPS6293662A (ja) * | 1985-10-18 | 1987-04-30 | Fuji Photo Film Co Ltd | 酸化型補酵素を含有する乾式分析要素 |
JPS62151200A (ja) | 1985-12-24 | 1987-07-06 | Unitika Ltd | マグネシウムイオン定量用試薬 |
US4779754A (en) * | 1987-07-15 | 1988-10-25 | Ecolab Inc. | Draining lid |
JPH06153991A (ja) | 1992-11-18 | 1994-06-03 | Unitika Ltd | ホスファターゼ測定試薬 |
JPH06303996A (ja) | 1993-04-16 | 1994-11-01 | Unitika Ltd | アルカリホスフォターゼ測定法と測定試薬 |
JP3203108B2 (ja) * | 1993-08-26 | 2001-08-27 | 協和メデックス株式会社 | グルコース−6−リン酸デヒドロゲナーゼの安定化方法 |
JP3505261B2 (ja) | 1995-03-17 | 2004-03-08 | 株式会社三徳 | Sm−Co系永久磁石材料、永久磁石及びその製造法 |
CA2223921A1 (en) * | 1995-06-07 | 1996-12-19 | Francis C. Szoka, Jr. | Stabilization of polynucleotide complexes |
US5817467A (en) * | 1995-11-16 | 1998-10-06 | Kyowa Medex Co., Ltd. | Method for quantitatively determining creatinine kinase and a reagent therefor |
JPH1033196A (ja) | 1996-07-23 | 1998-02-10 | Unitika Ltd | 試験片 |
SE9702680D0 (sv) * | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
US6130054A (en) * | 1997-12-19 | 2000-10-10 | Unitika Ltd. | Test strip for creatine kinase activity measurement |
JPH11253193A (ja) | 1997-12-19 | 1999-09-21 | Unitika Ltd | クレアチンキナーゼ活性測定用試験片 |
JP2001061498A (ja) | 1999-08-31 | 2001-03-13 | Oriental Yeast Co Ltd | 還元型補酵素溶液 |
EP1114997B1 (en) * | 1999-12-28 | 2009-09-30 | ARKRAY, Inc. | Blood testing tool |
DE10001529A1 (de) | 2000-01-15 | 2001-07-19 | Roche Diagnostics Gmbh | Stabilisierte Coenzym-Lösungen und deren Verwendung zur Bestimmung von Dehydrogenasen bzw. deren Substrate |
US6867012B2 (en) * | 2000-12-05 | 2005-03-15 | Toyo Boseki Kabushiki Kaisha | Determination method of biological component and reagent kit used therefor |
JP2002198664A (ja) * | 2000-12-26 | 2002-07-12 | Seiko Instruments Inc | 携帯電子機器 |
JP4651237B2 (ja) * | 2001-08-10 | 2011-03-16 | シスメックス株式会社 | 還元型ニコチンアミドアデニンジヌクレオチド類の安定化方法及び試薬 |
US7501053B2 (en) * | 2002-10-23 | 2009-03-10 | Abbott Laboratories | Biosensor having improved hematocrit and oxygen biases |
US7879567B2 (en) | 2004-10-05 | 2011-02-01 | Asahi Kasei Pharma Corporation | Method for stabilizing coenzyme and composition therefor |
-
2005
- 2005-10-05 US US11/576,048 patent/US7879567B2/en not_active Expired - Fee Related
- 2005-10-05 WO PCT/JP2005/018424 patent/WO2006038647A1/ja active Application Filing
- 2005-10-05 JP JP2006539313A patent/JP4986281B2/ja not_active Expired - Fee Related
-
2010
- 2010-12-23 US US12/977,874 patent/US8026075B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5743684A (en) * | 1980-08-29 | 1982-03-11 | Toyo Jozo Co Ltd | Preparation of maltose dehydrogenase |
JPH03505261A (ja) * | 1989-03-23 | 1991-11-14 | バンス,ロジャー・アブラハム | 液体移送装置 |
JPH10276785A (ja) * | 1997-03-31 | 1998-10-20 | Kureha Chem Ind Co Ltd | 組換え型トレハロースホスホリラーゼをコードする遺伝子、その遺伝子を含むベクター、その遺伝子で形質転換された形質転換体及びこの形質転換体を用いて組換え型トレハロースホスホリラーゼを製造する方法 |
WO2001094370A1 (fr) * | 2000-06-07 | 2001-12-13 | Wako Pure Chemical Industries, Ltd. | Derives de coenzymes et enzymes appropries |
JP2005304483A (ja) * | 2004-03-24 | 2005-11-04 | Asahi Kasei Pharma Kk | アルカリフォスファターゼ測定法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010000027A (ja) * | 2008-06-19 | 2010-01-07 | Denka Seiken Co Ltd | 新規検査方法及びそれに用いる検査キット |
JP2021001890A (ja) * | 2015-10-07 | 2021-01-07 | セルマ・ダイアグノスティクス・アンパルトセルスカブSelma Diagnostics Aps | デジタル計数のためのフローシステムおよび方法 |
JP7072274B2 (ja) | 2015-10-07 | 2022-05-20 | セルマ・ダイアグノスティクス・アンパルトセルスカブ | デジタル計数のための方法 |
US11693001B2 (en) | 2015-10-07 | 2023-07-04 | Selma Diagnostics Aps | Flow system and methods for digital counting |
Also Published As
Publication number | Publication date |
---|---|
JP4986281B2 (ja) | 2012-07-25 |
JPWO2006038647A1 (ja) | 2008-05-15 |
US20080318256A1 (en) | 2008-12-25 |
US20110159564A1 (en) | 2011-06-30 |
US7879567B2 (en) | 2011-02-01 |
US8026075B2 (en) | 2011-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10625242B2 (en) | Substrates and methods for collection, stabilization and elution of biomolecules | |
Lin et al. | Highly sensitive colorimetric immunosensor for influenza virus H5N1 based on enzyme-encapsulated liposome | |
AU2015250915B2 (en) | Substrates and methods for collection, stabilization and elution of biomolecules | |
JPS63294799A (ja) | グルコ−ス及び1,5−アンヒドログルシト−ルの同時測定法 | |
CN106565809A (zh) | 一种β半乳糖苷酶的酶供体偶联物及其在甘胆酸检测中的用途 | |
CN105241873A (zh) | 一种脂肪酶检测试剂盒 | |
WO2006038647A1 (ja) | 補酵素の安定化方法およびその組成物 | |
CN100365409C (zh) | 一种测定低密度脂蛋白胆固醇的试剂及制备方法 | |
EP0342586B1 (en) | Assay device with gradientregulated localized signal | |
WO2001023536A1 (fr) | Stabilisation de la thrombine et compositions | |
US20180321202A1 (en) | Methods and devices for detecting methanol poisoning using formate oxidase | |
JP2681635B2 (ja) | 分析感度及び分析精度を向上させる方法 | |
Benavidez et al. | Physicochemical properties of a mucin/chitosan matrix used for the development of an oxalate biosensor | |
Sakata et al. | Selective assay for endotoxin using poly (ε-lysine)-immobilized Cellufine and Limulus amoebocyte lysate (LAL) | |
JP4639757B2 (ja) | 電解質測定用組成物 | |
JP4557571B2 (ja) | フルクトシルペプチドオキシダ−ゼの安定化方法 | |
US11534504B2 (en) | Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof | |
JP2001013141A (ja) | 免疫クロマトグラフィー用吸水性材料 | |
JP4616575B2 (ja) | タンパク質の膜固定化方法 | |
CA1320899C (en) | Turbidimetric method for the determination of serum lipase | |
US6818415B2 (en) | Sodium activation of amylase | |
CN113267390A (zh) | 一种用于滤纸干血片的检测标志物洗脱液及其应用 | |
FR2927171A1 (fr) | Procede de detection et/ou de quantification et/ou d'identification in vitro de bacteries dans un materiau biologique | |
CN106290841A (zh) | 霍乱弧菌o1乳胶法检测试剂盒 | |
JP2009543062A (ja) | マーカーとしてサッカリドを使用する摂取可能な製品の真正性の認証 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006539313 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11576048 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05790548 Country of ref document: EP Kind code of ref document: A1 |